By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AstraZeneca Pharmaceuticals LP 

Boston R&D Site
35 Gatehouse Drive
Waltham  Massachusetts  02451  U.S.A.
Phone: 781-839-4000 Fax: n/a


At AstraZeneca, science and patients are at the heart of everything we do. As one of the world’s leading biopharmaceutical companies, AstraZeneca operates in more than 100 countries, producing innovative medicines used by millions of patients worldwide. Our expertise spans the entire life-cycle of a medicine and we have a unique combination of capabilities in small molecules, biologics, immunotherapies and protein engineering.

With our North America Commercial Headquarters in Wilmington, DE; one of three global Research and Development (R&D) centers in Gaithersburg, MD; and other R&D, manufacturing and office locations across the country, AstraZeneca’s U.S. operations are integral to our global business and to our efforts to make a meaningful difference in healthcare.

Commitment to Patients
Everything we do at AstraZeneca is driven by our commitment to improving the lives of patients – whether we’re working to reach more people with our medicines, applying distinctive science to developing the next generation of treatments or collaborating with others in the fight against disease.

We are focused on understanding and helping to meet the needs of people facing serious health challenges, and our skills and resources are concentrated on those therapy areas where we believe we can make the most difference: oncology; cardiovascular and metabolic disease; and respiratory, inflammatory and autoimmune disease. Alongside this, we remain active in infection, neuroscience and gastrointestinal disease through select opportunities.

Scientific Leadership
At AstraZeneca, we push the boundaries of science to deliver medicines that transform the lives of people around the world. Globally, AstraZeneca’s research investment totaled more than $4 billion in 2013. At the end of 2013, we had 99 pipeline projects, including 85 in the clinical development phase and 14 either approved, launched or filed.

AstraZeneca’s Gaithersburg, MD campus is one of three global strategic R&D centers and home to MedImmune, the global biologics research and development arm of AstraZeneca. MedImmune is pioneering innovative research and exploring novel pathways across AstraZeneca’s key therapeutic areas – with a robust pipeline of more than 120 biologics, including more than 30 in clinical development.

In addition, AstraZeneca’s Boston R&D site in Waltham, MA employs hundreds of talented AstraZeneca researchers, scientists and support staff representing more than 30 nationalities – and serves as the company’s headquarters for small-molecule discovery research in North America and global infectious disease research, with an additional focus on oncology drug research.

Collaboration as a Way of Life
We believe that some of the most exciting science comes from external collaborations. We have approximately 850 current industry and academic collaborations or partnerships around the world.
By sharing new ideas and enabling scientific innovation to cross boundaries between companies, academia, government and nonprofit organizations, we can accelerate new ideas into innovative medicines. The AstraZeneca Open Innovation platform ( has been created to help us do just that.

Key Locations
Worldwide Headquarters:
Cambridge, UK
North America Headquarters:
1800 Concord Pike
Wilmington, Delaware 19850
Phone: 302-886-3000
North America Strategic R&D Center:
Gaithersburg, MD

Key Statistics

Ownership: Public

Web Site: AstraZeneca Pharmaceuticals LP
Employees: Over 51,500 Worldwide
Symbol: AZN

Big Pharma


Company News
New First-in-Pediatrics Trial At Children's Hospital Los Angeles To Test AstraZeneca Pharmaceuticals LP (AZN)'s Durvalumab For Certain Cancers 8/18/2016 9:48:54 AM
Court Rejects Teva Pharmaceutical Industries Limited (TEVA) Appeal Over AstraZeneca Pharmaceuticals LP (AZN)'s Cholesterol Drug Crestor 12/2/2011 7:20:36 AM
AstraZeneca Pharmaceuticals LP (AZN) Release: Saturn Demonstrated Effect of Intensive Statin Treatment on Reducing Atherosclerosis 11/15/2011 7:13:50 AM
AstraZeneca PLC (AZN) (JOBS) Plans Local Job Cuts, Report Says 9/14/2009 7:57:44 AM
AstraZeneca Pharmaceuticals LP (AZN) Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology 6/1/2009 9:21:54 AM
Par Pharmaceutical, Inc. Halts Shipment of Budesonide Inhalation Suspension; Court Granted AstraZeneca Pharmaceuticals LP (AZN)'s Motion for Temporary Restraining Order Halting Sales of Teva Pharmaceutical Industries Limited (TEVA)'s Generic Pulmicort Respules 11/21/2008 7:10:34 AM
Statin Might Help More People Fight Heart Disease Than Thought, Brigham and Women's Hospital Study 11/10/2008 7:33:12 AM
Graffinity Pharmaceuticals GmbH And AstraZeneca Pharmaceuticals LP (AZN) Enter Into Multi-Target Drug Discovery Alliance 10/28/2008 2:47:44 PM
PreMD Inc. (PME) Provides Corporate Update 9/16/2008 11:53:26 AM
Phase III Study of Abbott Laboratories (ABT)' Investigational TriLipix(TM) in Combination With AstraZeneca Pharmaceuticals LP (AZN)'s CRESTOR(R) Meets Primary Endpoints on Key Lipids 6/2/2008 11:03:02 AM